Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Ami Vijay DesaiAndrew L GilmanMehmet Fevzi OzkaynakArlene NaranjoWendy B LondonSheena C TenneyMitchell B DiccianniJacquelyn A HankMarguerite T ParisiBarry L ShulkinMalcolm A SmithJeffrey A MoscowHiroyuki ShimadaKatherine K MatthaySusan L CohnJohn M MarisRochelle BagatellPaul M SondelJulie R ParkAlice Lin-Tsing YuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Analysis of a cohort assigned to immunotherapy after cessation of random assignment on ANBL0032 confirmed previously described survival and toxicity outcomes. EFS was highest among patients with end-induction complete response/very good partial response. Among patients with available data, higher dinutuximab levels and FCGR3A genotype were associated with superior EFS. These may be predictive biomarkers for dinutuximab therapy.